- Home
- LOAN vs DYAI Comparison
LOAN vs DYAI Comparison
Compare LOAN & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- DYAI
- Stock Information
- Founded
- LOAN 1989
- DYAI 1979
- Country
- LOAN United States
- DYAI United States
- Employees
- LOAN N/A
- DYAI N/A
- Industry
- LOAN Real Estate Investment Trusts
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOAN Real Estate
- DYAI Health Care
- Exchange
- LOAN Nasdaq
- DYAI Nasdaq
- Market Cap
- LOAN 61.4M
- DYAI 54.4M
- IPO Year
- LOAN 1999
- DYAI 2004
- Fundamental
- Price
- LOAN $5.67
- DYAI $1.50
- Analyst Decision
- LOAN
- DYAI Strong Buy
- Analyst Count
- LOAN 0
- DYAI 1
- Target Price
- LOAN N/A
- DYAI $6.00
- AVG Volume (30 Days)
- LOAN 20.8K
- DYAI 213.3K
- Earning Date
- LOAN 03-10-2025
- DYAI 11-12-2024
- Dividend Yield
- LOAN 8.11%
- DYAI N/A
- EPS Growth
- LOAN 6.53
- DYAI N/A
- EPS
- LOAN 0.49
- DYAI N/A
- Revenue
- LOAN $7,394,068.00
- DYAI $3,364,548.00
- Revenue This Year
- LOAN N/A
- DYAI $51.30
- Revenue Next Year
- LOAN N/A
- DYAI $73.26
- P/E Ratio
- LOAN $11.57
- DYAI N/A
- Revenue Growth
- LOAN 5.79
- DYAI 13.82
- 52 Week Low
- LOAN $4.60
- DYAI $0.93
- 52 Week High
- LOAN $5.90
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- LOAN 57.76
- DYAI 42.12
- Support Level
- LOAN $5.30
- DYAI $1.45
- Resistance Level
- LOAN $5.70
- DYAI $1.79
- Average True Range (ATR)
- LOAN 0.12
- DYAI 0.24
- MACD
- LOAN 0.00
- DYAI -0.05
- Stochastic Oscillator
- LOAN 74.00
- DYAI 7.25
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.